SG11201912454SA - Virus-like particles comprising zika antigen - Google Patents

Virus-like particles comprising zika antigen

Info

Publication number
SG11201912454SA
SG11201912454SA SG11201912454SA SG11201912454SA SG11201912454SA SG 11201912454S A SG11201912454S A SG 11201912454SA SG 11201912454S A SG11201912454S A SG 11201912454SA SG 11201912454S A SG11201912454S A SG 11201912454SA SG 11201912454S A SG11201912454S A SG 11201912454SA
Authority
SG
Singapore
Prior art keywords
virus
particles
zika antigen
zika
antigen
Prior art date
Application number
SG11201912454SA
Inventor
Velasco Cimica
Original Assignee
American Type Culture Collection Atcc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Type Culture Collection Atcc filed Critical American Type Culture Collection Atcc
Publication of SG11201912454SA publication Critical patent/SG11201912454SA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24123—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
SG11201912454SA 2017-06-23 2018-06-22 Virus-like particles comprising zika antigen SG11201912454SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762524440P 2017-06-23 2017-06-23
PCT/US2018/039079 WO2018237313A1 (en) 2017-06-23 2018-06-22 Virus-like particles comprising zika antigen

Publications (1)

Publication Number Publication Date
SG11201912454SA true SG11201912454SA (en) 2020-01-30

Family

ID=64737840

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201912454SA SG11201912454SA (en) 2017-06-23 2018-06-22 Virus-like particles comprising zika antigen

Country Status (6)

Country Link
US (1) US11179460B2 (en)
CN (1) CN111132692A (en)
BR (1) BR112019027737A2 (en)
MX (1) MX2019015925A (en)
SG (1) SG11201912454SA (en)
WO (1) WO2018237313A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3684405A2 (en) * 2017-09-21 2020-07-29 Emergex Vaccines Holdings Ltd MHC Class I Associated Peptides for Prevention and Treatment of Zika Virus
US11066448B2 (en) * 2018-05-11 2021-07-20 Buck Institute For Research On Aging Zika as a cell penetrating peptide for delivery to the brain
AU2019310347A1 (en) * 2018-07-23 2021-03-04 The University Of Adelaide Zika virus vaccine
MX2022005498A (en) * 2019-11-07 2022-08-11 Inst Microbiology Cas Zika/dengue vaccine and application thereof.
MX2022010956A (en) * 2020-03-03 2022-10-07 Mayo Found Medical Education & Res Zika virus polypeptides.

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ302092B6 (en) * 1998-02-12 2010-10-06 Immune Complex, Corporation Modified hepatitis B core protein conjugate, particles thereof, inoculum and process for inducing antibodies
DE60336902D1 (en) * 2002-07-19 2011-06-09 Cytos Biotechnology Ag VACCINE COMPOSITIONS CONTAINING AMYLOID BETA 1-6 ANTIGENARRAYS
US7320795B2 (en) * 2003-07-30 2008-01-22 Vaccine Research Institute Of San Diego Rodent hepatitis B virus core proteins as vaccine platforms and methods of use thereof
US10799575B2 (en) * 2015-06-25 2020-10-13 Technovax, Inc. Flavivirus and alphavirus virus-like particles (VLPS)

Also Published As

Publication number Publication date
US11179460B2 (en) 2021-11-23
US20200171143A1 (en) 2020-06-04
WO2018237313A1 (en) 2018-12-27
BR112019027737A2 (en) 2020-09-15
CN111132692A (en) 2020-05-08
MX2019015925A (en) 2020-08-06

Similar Documents

Publication Publication Date Title
HK1246654A1 (en) Virus-like particle with efficient epitope display
SG10201913630YA (en) Zika virus vaccine
HK1248718A1 (en) Anti-cd40 antibodies and uses thereof
SI3393510T1 (en) Zika virus vaccine
EP3419660A4 (en) Novel vaccines against zika virus
SG11201912454SA (en) Virus-like particles comprising zika antigen
EP3215520A4 (en) Cancer immunotherapy using virus particles
IL271182A (en) Cerium based particles
GB201613191D0 (en) Zika virus vaccine
IL247614B (en) Methods and compositions for modifying the immune response
EP3200831A4 (en) Vaccines having an antigen and interleukin-21 as an adjuvant
IL247100A0 (en) Anti cd84 antibodies, compositions comprising same and uses thereof
EP3403671C0 (en) Vaccine containing immobilized virus particles
EP3393456A4 (en) Immune cell-targeted particles
HK1253030A1 (en) Piv5-based amplifying virus-like particles
GB201701573D0 (en) Virus-like particle
DK3368068T3 (en) Virus-like particles with efficient epitope display
HK1246207A1 (en) Lipid-encapsulated gas microsphere compositions and related methods
SG10202010435XA (en) Improved method for producing virus like particles
EP3347044A4 (en) Bird flu vaccine combination comprising virus-like particles and novel adjuvants
EP3365010C0 (en) Cytotoxic immunostimulating particles and uses thereof
GB201910651D0 (en) Virus-like particle
EP3170509A4 (en) Vaccine containing virus-like particles
IL277680A (en) Packaging oligonucleotides into virus-like particles
EP3102590A4 (en) Antigenic epitopes from ebv gp350/220 and uses thereof